Amarin's Vascepa granted priority review status from Health Canada

|About: Amarin Corporation plc (AMRN)|By:, SA News Editor

Health Canada grants priority review status for Amarin's (NASDAQ:AMRN) licensee, HLS Therapeutics' (OTCPK:HLTRF) New Drug Submission (“NDS”) for Vascepa (icosapent ethyl) capsules.

HLS Therapeutics anticipates filing the NDS in April, seeking approval to market and sell Vascepa in Canada to reduce the risk of ischemic cardiovascular events in statin-treated patients with elevated triglycerides and other risk factors.

Priority review shortens the review the review period to 215 calendar days versus 355 days for a standard review.

AMRN shares are up 1% premarket.

Subscribe for full text news in your inbox